An international in-vitro diagnostics leader, DiaSorin SpA develops, manufactures and commercialises reagent kits for clinical analysis laboratories. Heading a group of 20 companies with offices in Europe, the United States and Central and South America, DiaSorin is listed on the Italian stock exchange.
To reaffirm and consolidate DiaSorin’s brand reputation in the Italian market. Since its foundation, the company has been acclaimed for its positive business model. The communications highlighted this best practice, focusing not only on the company’s performance and results, but equally on its business and management format, going beyond statutory reporting to leverage its notability as an international group.